Micreos Pharma announces success of its antibacterial enzyme that “selectively eliminates” pathogens

  18 April 2022

Micreos Pharmaceuticals’s novel antibacterial enzyme has been proved to be effective in selectively targeting and killing the harmful Staphylococcus aureus bacterial pathogen, as per the company’s study findings which it announced on Saturday. 

According to the company, the enzyme, XZ.700, eliminated the pathogen while maintaining a healthy microbiome and preventing antimicrobial resistance (AMR). These findings can be a crucial step in tackling AMR.

The pharma company maintained that XZ.700 is the first of many innovative endolysins in its portfolio and it’s essential as the first molecule the company will market. The findings of the study were published in Antimicrobial Agents and Chemotherapy.

Further reading: FE Healthcare
Author(s): FE Healthcare
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!